Evommune reports Phase 2a data for EVO301 in atopic dermatitis at EADV
The IL-18 inhibitor hit its primary endpoint at Week 12 and the company plans to start a Phase 2b subcutaneous trial in mid-2027.
SEC filing
Latest
5 stories
Today
Wednesday, September 23
Evommune to present Phase 2a EVO301 atopic dermatitis data at EADV 2026
The late-breaker presentation on October 1 in Vienna will detail topline results from the IL-18 binding protein trial, with a Phase 2b study planned for mid-2027.
SEC filing
Tuesday, September 8
Evommune's EVO756 fails Phase 2b atopic dermatitis trial, shifts focus to EVO301
The company will stop developing EVO756 for atopic dermatitis but continue testing it for migraine, while advancing its IL-18BP candidate EVO301.
SEC filing
Thursday, August 6
Evommune reports Q2 2026 results, sets EVO756 AD data for September
The company also discontinued EVO756 development in chronic spontaneous urticaria and pointed to cash lasting through 2028.
SEC filing
Thursday, July 30
Evommune doses first patient in Phase 2b trial of EVO756 for migraine prevention
The company's oral MRGPRX2 antagonist enters mid-stage testing with roughly 330 patients, and top-line results are expected in 2027.
SEC filing